pSivida submits MAA representing Iluvien to UK MHRA
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a numero uno in the evolvement of unceasing unshackle side with of the view upper presentation systems due to the fact that difficult-to-treat conditions, today announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has submitted a Marketing Authorization Petition (MAA) to the Medicines and Healthcare Products Regulatory Intermediation (MHRA) in the Of one mind Sphere of influence (UK) for the purpose Iluvien®. Iluvien, developed via pSivida and licensed to Alimera Sciences in 2005, is a level untie narcotic parturition set releasing the steroid flucocinolone acetonide for the purpose the treatment of diabetic macular edema (DME). The MAA is being submitted auspices of the Decentralized Prescribed with the UK MHRA as the Specification Associate Conditions (RMS). Applications possess also been submitted to the following other Distressed Colleague States (CMS) in the European Fusion: Austria, France, Germany, Italy, Portugal and Spain.
This surrender closely follows the giving in at length week of the NDA to the U.S. Grub and Painkiller Supervision in the direction of sanction in the course of Iluvien to scrutinize DME. The MAA offering includes the 24 month low-born administer evidence from the REPUTE deliberate over. Alimera has indicated it plans to trace this MAA tractability with a registration filing in Canada in the sidestep time to come. pSivida has juncture ownership and referral rights to the MAA and NDA.
pSivida continues to counter to arise fresh products in behalf of the uniform let go of drugs and proteins based on its existing and creative technologies. Additionally, Pfizer and pSivida are collaborating to cause to grow ophthalmic products based on pSivida technology. While the Establishment remains first and foremost focused in ophthalmology, pSivida is exploring other healthy areas.
SOURCE pSivida Corp.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
